After weeks of negotiations and last-minute drama, the House GOP has pulled its Obamacare replacement bill after it became clear that there were not enough votes to pass it.
This week, the top stories in managed care included last-minute changes to Republicans' bill to repeal the Affordable Care Act; a lack of votes to pass the GOP health bill; and promising study results on PCSK9 inhibitors and SGLT2 inhibitors.
The study identified a target that reacts to the implantation of biomedical materials. The findings could to improvements in insulin pump infusion sets and CGM sensors.
As House Speaker Paul Ryan, R-Wisconsin, and President Donald Trump endeavored to round up enough Republican votes to pass the American Health Care Act this week, a major sticking point for some reluctant GOP legislators was the inclusion of the Affordable Care Act’s essential health benefits in the replacement bill. Reports indicate that the essential health benefits requirement will be cut from the bill that will go to the House for a vote today.
Debate on the House floor covered familiar ground: Republicans called for an end to the individual mandate and decried rising premiums and fewer insurers on the exchanges, while Democrats blasted the proposed cuts to Medicaid. The late change to cut essential health benefits cost House leaders a key moderate vote.
The initiative includes targeted efforts in 7 cities to reduce the number of "unhealthy days," a metric devised by CDC to gauge physical and mental well-being.
As part of Republicans’ fast and furious push to repeal the Affordable Care Act, there is a vote scheduled today in the House of Representatives on the American Health Care Act. However, there have been serious doubts in the days leading up to the Thursday vote that there were enough votes in the House to pass the bill.
The changes were designed to appease the most conservative House Republicans, whose votes are needed because no Democrats will support the bill. A House floor vote could come by Thursday.
On the second day of the 22nd Annual Conference of the National Comprehensive Cancer Network (NCCN), Kilian E. Salerno, MD, of the Roswell Park Cancer Institute, walked the audience through updates to the NCCN Guidelines, explaining clinical situations in which radiation is indicated, appropriate targets of radiation treatment, and optimal approaches for minimizing toxicity.
At the 22nd Annual Conference of the National Comprehensive Cancer Network, held March 23-25, 2017, in Orlando, FL, Gregory J. Riely, MD, PhD, Memorial Sloan Kettering Cancer Center, spoke about the what, when, and how of biomarker testing in non-small cell lung cancer.
Dr Matthew Gubens Highlights Immunotherapy Advances and Combinations for Lung Cancer
Recent research has shown the potential of immunotherapy treatments for treating lung cancer, explained Matthew Gubens, MD, MS, assistant clinical professor of thoracic oncology at the University of California, San Francisco. Dr Gubens also spoke about oncologists’ hopes for using immuno-oncology agents in combination with one another or with chemotherapy.
Dr Moon S. Chen Jr Discusses Strategies for Reducing Cancer Disparities in Asian Americans
The unique cancer burden among Asian Americans calls for a multifaceted strategy to address these disparities, according to Moon S. Chen Jr, PhD, MPH, professor of hematology and oncology at UC Davis Comprehensive Cancer Center and principal investigator of The National Center for Reducing Asian American Cancer Health Disparities.
The advance of CAR-T technology and the rise of immuno-oncology alongside emerging new payment models highlight the annual review in Evidence-Based Oncology™, which looks at how researchers are harnessing the immune system to bring unprecedented results in cancer care.
As health plans ramp up efforts to “coach” patients with diabetes and other chronic diseases, a study in The American Journal of Managed Care® finds that customizing these efforts to patients’ knowledge and needs reduces hospital visits and improves some health measures.
Live Spring meeting will offer unique perspectives from industry leaders on current and evolving healthcare delivery models
The American Journal of Managed Care® presents its annual special issue of Evidence-Based Oncology™ featuring full coverage of the 58th annual meeting of the American Society of Hematology. CAR T-cell treatments gained notice, as did sessions on patients’ improving quality of life and addressing the high costs of new therapies.
Clinical Pathways Compendium
COPD Compendium
Diabetes Compendium
GI Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Rare Disease Compendium
Reimbursement Compendium
Know Your News
HF Compendium